Open Access
Review
Table 3.
Antimalarial compounds and clinical trial phases.
| Product name | Clinical trial phase | Target stage/site |
|---|---|---|
| Malaria vaccine 257049 | Phase III | Pre-erythrocytic stages, Erythrocytic stages |
| FMP011/AS01B | Phase I/II trial | Pre-erythrocytic stages, Erythrocytic stages |
| FMP2.1/AS02A | Phase II | Pre-erythrocytic stages, Erythrocytic stages |
| FMP1/AS02A | Phase II completed | Pre-erythrocytic stages, Erythrocytic stages |
| RTS, S/AS02D | Phase II completed | Pre-erythrocytic stages, Erythrocytic stages |
| Recombinant hybrid GMZ 2 [GLURP + MSP 3] | Phase I | Erythrocytic stage |
Malaria vaccine candidates (VAC045)
|
Phase I | Pre-erythrocytic stage |
| Phase II completed | ||
| Plasmodium falciparum malaria protein 010 (FMP010) | Phase I completed | Erythrocytic stage |
| Falciparum malaria protein (FMP012), E. Coli-expressed PfCelTOS | Phase I completed | Pre-erythrocytic stage |
| Peptides MSP3 long synthetic peptide 30 micrograms of MSP3 LSP | Phase II | Erythrocytic stage |
|
Phase III completed | Erythrocytic stage |
| OZ439 (second generation endoperoxide) | Phase II | Erythrocytic stage |
| KAE609 | Phase II completed | Post-erythrocytic stage |
| NITD609 (spiroindolone class, plant Product) | Phase II | Post-erythrocytic stage |
| Ferroquine (SSR-97193, FQ), | Phase II completed | Erythrocytic stage |
| Trioxaquine SAR116242 | Preclinical | Erythrocytic stage |
| MK4815 | Preclinical | Erythrocytic stage |
| GNF156; an imidazolopiperazine | Phase II | Pre-erythrocytic, Erythrocytic Post-erythrocytic stage |
| DSM265 selective triazolopyrimidine-based inhibitor (first compound to target DHODH) | Phase I | Erythrocytic stage |
| P218 inhibitor of DHFR | Phase I | Erythrocytic stage |
| CDRI97/98 | Phase I | Erythrocytic stage |
| CDRI9778 | Phase I | Erythrocytic stage |
| Methylene blue | Phase II | Erythrocytic stage |
| Argemone mexicana | Phase II | NA |
| Rapid diagnostic test for malaria | Phase IV completed | Based on Immuno-detection of HRP2, pLDH |
Source: http://www.clinicaltrials.gov/
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.